UPDATE: Oppenheimer Starts Jazz Pharmaceuticals (JAZZ) at Outperform
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.95 +0.39%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
(Updated - May 23, 2012 7:19 AM EDT)
Oppenheimer initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform. PT $66.00.
The firm comments, "We believe JAZZ's lead marketed product, Xyrem, for the treatment of excessive daytime sleepiness (EDS) and cataplexy, will continue to bolster top-line growth as JAZZ continues to leverage price increases with volume growth. We currently estimate US peak sales of ~$1.1B in 2020. JAZZ's recently announced acquisition of EUSA Pharmaceuticals not only provides an EU commercial footing but also serves as a basis for a cancer portfolio that JAZZ can expand on longer term. We believe JAZZ may further increase shareholder value via additional business development activities centering on specialty and/or orphan products."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $43.79 yesterday.
Oppenheimer initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform. PT $66.00.
The firm comments, "We believe JAZZ's lead marketed product, Xyrem, for the treatment of excessive daytime sleepiness (EDS) and cataplexy, will continue to bolster top-line growth as JAZZ continues to leverage price increases with volume growth. We currently estimate US peak sales of ~$1.1B in 2020. JAZZ's recently announced acquisition of EUSA Pharmaceuticals not only provides an EU commercial footing but also serves as a basis for a cancer portfolio that JAZZ can expand on longer term. We believe JAZZ may further increase shareholder value via additional business development activities centering on specialty and/or orphan products."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $43.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
- Chardan Starts QumulusAI (QMLS) at Buy
- Deutsche Bank Starts Hochtief AG (HOT:GR) (HOCFF) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
